Beta Bionics Statistics
Total Valuation
Beta Bionics has a market cap or net worth of $960.05 million. The enterprise value is $889.31 million.
| Market Cap | 960.05M |
| Enterprise Value | 889.31M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Beta Bionics has 42.86 million shares outstanding.
| Current Share Class | 42.86M |
| Shares Outstanding | 42.86M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +23.74% |
| Owned by Insiders (%) | 3.16% |
| Owned by Institutions (%) | 13.11% |
| Float | 41.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.82 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.22.
| Current Ratio | 4.62 |
| Quick Ratio | 3.82 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -711.95 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -51.33% |
| Revenue Per Employee | $182,247 |
| Profits Per Employee | -$190,708 |
| Employee Count | 291 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,349,105 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Beta Bionics had revenue of $53.03 million and -$55.50 million in losses. Loss per share was -$4.89.
| Revenue | 53.03M |
| Gross Profit | 29.26M |
| Operating Income | -40.58M |
| Pretax Income | -55.50M |
| Net Income | -55.50M |
| EBITDA | -39.37M |
| EBIT | -40.58M |
| Loss Per Share | -$4.89 |
Balance Sheet
The company has $60.90 million in cash and $7.30 million in debt, giving a net cash position of $53.60 million or $1.25 per share.
| Cash & Cash Equivalents | 60.90M |
| Total Debt | 7.30M |
| Net Cash | 53.60M |
| Net Cash Per Share | $1.25 |
| Equity (Book Value) | 32.87M |
| Book Value Per Share | -34.35 |
| Working Capital | 64.68M |
Cash Flow
In the last 12 months, operating cash flow was -$40.34 million and capital expenditures -$3.15 million, giving a free cash flow of -$43.49 million.
| Operating Cash Flow | -40.34M |
| Capital Expenditures | -3.15M |
| Free Cash Flow | -43.49M |
| FCF Per Share | -$1.01 |
Margins
Gross margin is 55.17%, with operating and profit margins of -76.52% and -104.64%.
| Gross Margin | 55.17% |
| Operating Margin | -76.52% |
| Pretax Margin | -104.64% |
| Profit Margin | -104.64% |
| EBITDA Margin | -74.24% |
| EBIT Margin | -76.52% |
| FCF Margin | n/a |
Dividends & Yields
Beta Bionics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -5.89% |
| FCF Yield | -4.61% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Beta Bionics has an Altman Z-Score of -4.06 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.06 |
| Piotroski F-Score | 1 |